Characterization and stability of tanshinone IIA solid dispersions with hydroxyapatite

Materials

Volumn 6, Issue 3, 2013, Pages 805-816

  Wang, Xiaopan ^a   Li, Li ^b   Huo, Wei ^a   Hou, Lulu ^a   Zhao, Zhiying ^a   Li, Weiguang ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Hydroxyapatite; Solid dispersions; TanIIA

Indexed keywords

DISSOLUTION BEHAVIOR; DISSOLUTION RATES; HYDROXYAPATITE (HAP); IN-VITRO DISSOLUTION; SIGNIFICANT DIFFERENCES; SOLID DISPERSION; SOLVENT EVAPORATION METHOD; TANIIA;

DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; FOURIER TRANSFORM INFRARED SPECTROSCOPY; FOURIER TRANSFORMS; HYDROXYAPATITE; SCANNING ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION;

DISPERSIONS;

EID: 84875845244     PISSN: None     EISSN: 19961944     Source Type: Journal    
DOI: 10.3390/ma6030805     Document Type: Article

References (44)

1. Wang, P.; Wu, X.; Bao, Y.; Fang, J.; Zhou, S.; Gao, J.; Pi, R.; Mou, Y.G.; Liu, P. Tanshinone IIA prevents cardiac remodeling through attenuating NAD (P)H oxidase-derived reactive oxygen species production in hypertensive rats. Pharmazie 2011, 66, 517-524.
2. Wei, Y.; Li, P.; Wang, C.; Peng, Y.; Shu, L.; Jia. X.; Ma, W.; Wang, B. Metabolism of tanshinone IIA, cryptotanshinone and tanshinone I from Radix Salvia miltiorrhiza in zebrafish. Molecules 2012, 17, 8617-8632.
3. Gao, J.; Yang, G.; Pi, R.; Li, R.; Wang, P.; Zhang, H.; Le, K.; Chen, S.; Liu, P. Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Transl. Res. 2008, 151, 79-87.
4. Li, X.B.; Wang, W.; Zhou, G.J.; Li, Y.; Xie, X.M.; Zhou, T.S. Production of salvianolic acid B in roots of Salvia miltiorrhiza (Danshen) during the post-harvest drying process. Molecules 2012, 17, 2388-2407.
5. Qiao, Z.; Ma, J.; Liu, H. Evaluation of the antioxidant potential of Salvia miltiorrhiza ethanol extract in a rat model of ischemia-reperfusion injury. Molecules 2011, 16, 10002-10012.
6. Fu, J.; Huang, H.; Liu, J.; Pi, R.; Chen, J.; Liu, P. TSIIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur. J. Pharmacol. 2007, 568, 213-221.
7. Hao, H.; Wang, G.; Cui, N.; Li, J.; Xie, L.; Ding, Z. Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion. Planta Med. 2006, 72, 1311-1317.
8. Yu, H.; Subedi, R.K.; Nepal, P.R.; Kim, Y.G.; Choi, H.K. Enhancement of solubility and dissolution rate of cryptotanshinone, tanshinone I and tanshinone IIA extracted from Salvia miltiorrhiza. Arch. Pharm. Res. 2012, 35, 1457-1464.
9. Chang, L.C.; Wu, C.L.; Liu, C.W.; Chuo, W.H.; Li, P.C.; Tsai, T.R. Preparation, characterization and cytotoxicity evaluation of tanshinone IIA nanoemulsions. J. Biomed. Nanotechnol. 2011, 7, 558-567.
10. Yu, X.Y.; Lin, S.G.; Zhou, Z.W.; Chen, X.; Liang, J.; Liu, P.Q.; Duan, W.; Chowbay, B.; Wen, J.Y.; Li, C.G.; Zhou, S.F. Role of P-glycoprotein in the intestinal absorption of TSIIA, a major active ingredient in the root of Salvia miltiorrhiza. Curr. Drug Metab. 2007, 8, 325-340.
11. Mao, S.J.; Hou, S.X.; Liang, Z.; Bi, Y.Q.; Wu, Y.; Li, H.; Jin, H. Ion-pair reversed-phase HPLC: Assay validation of sodium TSIIA sulfonate in mouse plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2006, 831, 163-168.
12. Wang, L.; Jiang, X.; Xu, W.; Li, C. Complexation of tanshinone IIA with 2-hydroxypropyl-betacyclodextrin: Effect on aqueous solubility, dissolution rate, and intestinal absorption behavior in rats. Int. J. Pharm. 2007, 341, 58-67.
13. Beak, I.H.; Kim, M.S. Improved supersaturation and oral absorption of dutasteride by amorphous solid dispersions. Chem. Pharm. Bull. 2012, 60, 1468-1473.
14. Potluri, R.H.; Bandari, S.; Jukanti, R.; Veerareddy, P.R. Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with Gelucire 50/13. Arch. Pharm. Res. 2011, 34, 51-57.
15. Planinšek, O.; Kovaèiè, B.; Vreèer, F. Carvedilol dissolution improvement by preparation of solid dispersions with porous silica. Int. J. Pharm. 2011, 406, 41-48.
16. Venkatesh, G.M.; Barnett, M.E.; Owusu-Fordjour, C.; Galop, M. Detection of low levels of the amorphous phase in crystalline pharmaceutical materials by thermally stimulated current spectrometry. Pharm. Res. 2001, 18, 98-103.
17. Willart, J.F.; Descamps, M. Solid state amorphization of pharmaceuticals. Mol. Pharm. 2008, 5, 905-920.
18. Greco, S.; Authelin, J.R.; Leveder, C.; Segalini, A. A practical method to predict physical stability of amorphous solid dispersions. Pharm. Res. 2012, 29, 2792-2805.
19. Bhugra, C.; Rambhatla, S.; Bakri, A.; Duddu, S.P.; Miller, D.P.; Pikal, M.J.; Lechuga-Ballesteros, D. Prediction of the onset of crystallization of amorphous sucrose below the calorimetric glass transition temperature from correlations with mobility. J. Pharm. Sci. 2007, 96, 1258-1269.
20. Hong, J.; Shah, J.C.; Mcgonagle, M.D. Effect of cyclodextrin derivation and amorphous state of complex on accelerated degradation of ziprasidone. J. Pharm. Sci. 2011, 100, 2703-2716.
21. Kojima, T.; Higashi, K.; Suzuki, T.; Tomono, K.; Moribe, K.; Yamamoto, K. Stabilization of a supersaturated solution of mefenamic acid from a solid dispersion with EUDRAGIT® EPO. Pharm. Res. 2012, 29, 2777-2791.
22. Qian, F.; Wang, J.; Hartley, R.; Tao, J.; Haddadin, R.; Mathias, N.; Hussain, M. Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications. Pharm. Res. 2012, 29, 2765-2776.
23. Al-Obaidi, H.; Ke, P.; Brocchini, S.; Buckton, G. Characterization and stability of ternary solid dispersions with PVP and PHPMA. Int J. Pharm. 2011, 419, 20-27.
24. Al-Obaidi, H.; Brocchini, S.; Buckton, G. Anomalous properties of spray dried solid dispersions. J. Pharm Sci. 2009, 98, 4724-4737.
25. Wu, J.X.; Yang, M.; van den Berg, F.; Pajander, J.; Rades, T.; Rantanen, J. Influence of solvent evaporation rate and formulation factors on solid dispersion physical stability. Eur. J. Pharm. Sci. 2011, 44, 610-620.
26. Bellucci, D.; Cannillo, V.; Sola, A. A New Highly Bioactive Composite for Scaffold Applications: A Feasibility Study. Materials 2011, 4, 339-354.
27. Jin, H.H.; Kim, D.H.; Kim, T.W.; Shin, K.K.; Jung, J.S.; Park, H.C.; Yoon, S.Y. In vivo evaluation of porous hydroxyapatite/chitosan-alginate composite scaffolds for bone tissue engineering. Int. J. Biol. Macromol. 2012, 51, 1079-1085.
28. Ishikawa, K. Bone Substitute Fabrication Based on Dissolution-Precipitation Reactions. Materials 2010, 3, 1138-1155.
29. Fu, S.; Ni, P.; Wang, B.; Chu, B.; Peng, J.; Zheng, L.; Zhao, X.; Luo, F.; Wei, Y.; Qian, Z. In vivo biocompatibility and osteogenesis of electrospun poly(ε-caprolactone)-poly(ethyleneglycol)-poly (ε-caprolactone)/nano-hydroxyapatite composite scaffold. Biomaterials 2012, 33, 8363-8371.
30. Venkatesan, J.; Kim, S.K. Effect of Temperature on Isolation and Characterization of Hydroxyapatite from Tuna (Thunnus obesus) Bone. Materials 2010, 3, 4761-4772.
31. Kong, L.; Gao, Y.; Cao, W.; Gong, Y.; Zhao, N.; Zhang, X. Preparation and characterization of nano-hydroxyapatite/chitosan composite scaffolds. J. Biomed. Mater. Res. A 2005, 75, 275-282.
32. Doostmohammadi, A.; Monshi, A.; Fathi, M.H.; Karbasi, S.; Braissant, O.; Daniels, A.U. Direct cytotoxicity evaluation of 63S bioactive glass and bone-derived hydroxyapatite particles using yeast model and human chondrocyte cells by microcalorimetry. J. Mater. Sci. Mater. Med. 2011, 22, 2293-2300.
33. Vohra, S.; Hennessy, K.M.; Sawyer, A.A.; Zhuo, Y.; Bellis, S.L. Comparison of mesenchymal stem cell and osteosarcoma cell adhesion to hydroxyapatite. J. Mater. Sci. Mater. Med. 2008, 19, 3567-3574.
34. Hennessy, K.M.; Clem, W.C.; Phipps, M.C.; Sawyer, A.A.; Shaikh, F.M.; Bellis, S.L. The effect of RGD peptides on osseointegration of hydroxyapatite biomaterials. Biomaterials 2008, 29, 3075-3083.
35. Wei, G.; Ma, P.X. Structure and properties of nano-hydroxyapatite/polymer composite scaffolds for bone tissue engineering. Biomaterials 2004, 25, 4749-4757.
36. Victor, S.P.; Sharma, C.P. Tryptophan complexed hydroxyapatite nanoparticles for immunoglobulin adsorption. J. Mater. Sci. Mater. Med. 2011, 22, 2219-2229.
37. Monkhouse, D.C.; Lach, J.L. Use of adsorbents in enhancement of drug dissolution II. J. Pharm. Sci. 1972, 61, 1435-1441.
38. Zhao, X.; Liu, X.; Gan, L.; Zhou, C.; Mo, J. Preparation and physicochemical characterizations of tanshinone IIA solid dispersion. Arch. Pharm. Res. 2011, 34, 949-959.
39. Li, J.; Liu, P.; Liu, J.P.; Zhang, W.L.; Yang, J.K.; Fan, Y.Q. Novel Tanshinone IIA ternary solid dispersion pellets prepared by a single-step technique: In vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 2012, 80, 426-432.
40. Shaltout, A.A.; Allam, M.A.; Moharram, M.A. FTIR spectroscopic, thermal and XRD characterization of hydroxyapatite from new natural sources. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2011, 83, 56-60.
41. Hwang, K.S.; Jeon, K.O.; Jeon, Y.S.; Kim, B.H. Hydroxyapatite forming ability of electrostatic spray pyrolysis derived calcium phosphate nano powder. J. Mater. Sci. Mater. Med. 2007, 18, 619-622.
42. Reves, B.T.; Jennings, J.A.; Bumgardner, J.D.; Haggard, W.O. Osteoinductivity Assessment of BMP-2 Loaded Composite Chitosan-Nano-Hydroxyapatite Scaffolds in a Rat Muscle Pouch. Materials 2011, 4, 1360-1374.
43. Kandori, K.; Oketani, M.; Wakamura, M. Effects of Ti(IV) substitution on protein adsorption behaviors of calcium hydroxyapatite particles. Colloids Surf. B Biointerfaces 2013, 101, 68-73.
44. Kennedy, M.; Hu, J.; Gao, P.; Li, L.; Ali-Reynolds, A.; Chal, B.; Gupta, V.; Ma, C.; Mahajan, N.; Akrami, A.; Surapaneni, S. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: A case study. Mol. Pharm. 2008, 5, 981-993.